Immuron CEO, Steven Lydeamore to host an investor webinar

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, invites investors to a live webcast hosted by CEO Steven Lydeamore on February 28, 2023, at 11:00 AM AEDT. Immuron specializes in developing oral immunotherapeutic products for gut-mediated diseases, with its flagship product, Travelan®, approved in Australia and Canada to reduce the risk of Travelers' Diarrhea. In the U.S., it is marketed as a dietary supplement. This event aims to provide insights into the company's product offerings and future plans.

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT). To register in advance for this webinar, please follow this link: https://us02web.zoom.us/webinar/register/WN_Gum4B9IDS-S6C1eMKr0Zqw After registering, you will receive a confirmation email containing information about joining the webinar.

This release has been authorised by the directors of Immuron Limited.

 COMPANY CONTACT:

 Steven Lydeamore
 Chief Executive Officer
 Ph: +61 (0)3 9824 5254
 info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).

For more information visit: http://www.immuron.com

FAQ

What is the date and time of Immuron's live webcast?

Immuron's live webcast is scheduled for February 28, 2023, at 11:00 AM Australian Eastern Standard Time (AEDT).

Who is hosting the Immuron Limited webcast?

The webcast will be hosted by Steven Lydeamore, the CEO of Immuron Limited.

What products does Immuron Limited offer?

Immuron Limited offers oral immunotherapeutic products, including Travelan®, which is indicated for reducing the risk of Travelers' Diarrhea.

Where can I register for the Immuron Limited webcast?

You can register for the Immuron Limited webcast by visiting the link provided in the press release or directly at their website.

What is the stock symbol for Immuron Limited?

The stock symbol for Immuron Limited is IMRN on NASDAQ and IMC on ASX.